This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Karo Pharma (KARB.F) Stock Overview

KARB.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Risk Analysis

Earnings have declined by 46.5% per year over past 5 years

Shares are highly illiquid

Interest payments are not well covered by earnings

Shareholders have been diluted in the past year

KARB.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW436,653 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

436,653 investors already sharing narratives

View all narratives

Karo Pharma AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Karo Pharma
Historical stock prices
Current Share Price	SEK 5.25
52 Week High	SEK 5.25
52 Week Low	SEK 5.25
Beta	0.10
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	28.05%
Change since IPO	310.16%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	KARB.F	US Pharmaceuticals	US Market
7D	0%	-3.0%	-0.2%
1Y	n/a	45.8%	14.8%

Return vs Industry: Insufficient data to determine how KARB.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how KARB.F performed against the US Market.

Price Volatility

Is KARB.F's price volatile compared to industry and market?
KARB.F volatility
KARB.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	8.8%
Market Average Movement	6.9%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

Stable Share Price: KARB.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine KARB.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1987	225	Christoffer Lorenzen	www.karopharma.com

Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands.

Karo Pharma AB (publ) Fundamentals Summary

How do Karo Pharma's earnings and revenue compare to its market cap?
KARB.F fundamental statistics
Market cap	US$1.54b
Earnings (TTM)	-US$17.68m
Revenue (TTM)	US$322.83m

4.8x

P/S Ratio

-86.9x

P/E Ratio

Is KARB.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KARB.F income statement (TTM)
Revenue	SEK 3.47b
Cost of Revenue	SEK 1.50b
Gross Profit	SEK 1.96b
Other Expenses	SEK 2.15b
Earnings	-SEK 189.85m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.69
Gross Margin	56.67%
Net Profit Margin	-5.48%
Debt/Equity Ratio	104.8%

How did KARB.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/11/08 20:04
End of Day Share Price	2022/08/11 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Karo Pharma AB (publ) is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Camilla Oxhamre	Carnegie Investment Bank AB
Olle Sjölin	Nordea Markets
Peter Abelin	Redeye